Christina Barrington, PharmD, of Priority Health, explained the keys to leading a successful managed care organization, as well as where she predicts the industry will be in the future.
Christina Barrington, PharmD, of Priority Health, discussed the key ingredients in a successful managed care organization and the resources she uses to stay up to date on health care and pharmacy industry trends. She also predicted where the managed care field will be in the future, taking into account emerging trends and innovations. Barrington discussed this topic at length during the AMCP Nexus session "Executive to Executive: Leading Managed Care Organizations Today" on October 17.
Barrington is currently Priority Health's vice president and chief pharmacy officer, leading both the pharmacy operations and clinical pharmacy teams. She is also AMCP's 2023-2024 Board of Directors president-elect.
Transcript
What are the key drivers to success in the managed care pharmacy industry and how do they contribute to the success of your organization?
As a pharmacy executive within my organization, and for other pharmacy executives, I think the key factors for being successful, 1 is education, having a vast knowledge of the profession and managed care, not only in pharmacy, but beyond pharmacy.
In other areas of the organization, a good business acumen, understanding the business and being able to see the numbers, understand those numbers, and have an impact on that. As far as staff development, being a mentor and a resource, not only for my staff, but for other staff members within our organization.
As a managed care executive, how do you stay up to date on the latest developments in the health care and pharmacy industries? Are there any specific resources you use to keep your organization informed?
We use all of the daily news feeds, Wall Street Journal, all of the press releases that come out on a daily basis; we scour those every day to keep track of what's happening in the news. We use resources like IPD Analytics to do our predictive modeling, look at trends, look at the pipeline, and clinical data.
We also do our own clinical literature searches on the internet. My team is very adept at doing that, and we try to keep the bias out of all of our reviews and analyses.
Where do you envision the managed care pharmacy field to be in the future? Are there any emerging trends or innovations that you believe will significantly impact the industry?
I think there's been a lot of change in the market. We're seeing things like Mark Cuban, Amazon Pharmacy. We're seeing, recently, Blue Cross Blue Shield of California announcing a different pharmacy model with regards to their PBM [pharmacy benefit manager].
I think it's the start of a lot of changes for us in managed care, and I think we're going to see many more programs being developed to help address the costs. We're going to see more of a cash option for many of our members outside of their traditional pharmacy benefit.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More